ClinConnect ClinConnect Logo
Search / Trial NCT00004568

Study of Inherited Neurological Disorders

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Feb 11, 2000

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Myopathy Muscular Dystrophy Motor Neuron Disease

ClinConnect Summary

This clinical trial is studying inherited neurological disorders, which are conditions that affect the brain, spinal cord, muscles, and nerves, and can be passed down through families. The goal of the study is to understand more about these disorders, including how they develop, their symptoms, and how they progress over time. Researchers are particularly interested in learning about the genetics of these conditions, as well as their emotional and behavioral impacts. Participants may include children and adults who have a known or suspected inherited neurological disorder, or family members who do not have these conditions but are related to someone who does.

If you or a family member is interested in participating, you will undergo a thorough medical and family history assessment, including a physical exam and possibly some tests like blood or urine tests, brain wave recordings, and imaging scans. The study aims to gather valuable information that could lead to better diagnosis and treatment options for these rare disorders. To be eligible, participants must be at least two years old and able to provide informed consent, or have a guardian who can do so. This research could help improve the understanding of these conditions and open the door for future studies.

Gender

ALL

Eligibility criteria

  • Participants include those with inherited neurological conditions based on the training and research needs of the Neurogenetics Branch program. There is no logical limit; however the total number of participants that can be enrolled in the protocol will be restricted. No more than 3,500 participants with either diagnosed or undiagnosed neurological conditions and their unaffected relatives will be enrolled in this evaluation and diagnostic protocol.
  • INCLUSION CRITERIA:
  • Participants will be eligible if they:
  • Have either a known or suspected, inherited neurological disease, OR are an unaffected relative (first-, second-, third, or higher degree relative) of a participant with a genetic neurological disease.
  • Have the ability to understand and sign an informed consent or have a parent/legal guardian to do so if they are minor children or a legal guardian to provide consent for adults without consent capacity.
  • Aged 2 years and above.
  • EXCLUSION CRITERIA:
  • Participants will not be eligible if they:
  • -Have a systemic disease that compromises the ability to provide adequate neurologic examination or diagnosis.An example of this would be a contagious disease that would compromise our ability to do an adequate neurological exam.

About National Institute Of Neurological Disorders And Stroke (Ninds)

The National Institute of Neurological Disorders and Stroke (NINDS) is a leading component of the National Institutes of Health (NIH), dedicated to advancing our understanding of the brain and nervous system through innovative research. NINDS sponsors and conducts clinical trials aimed at developing effective treatments and improving patient outcomes for a wide range of neurological disorders, including stroke, epilepsy, multiple sclerosis, and neurodegenerative diseases. By fostering collaboration among researchers, healthcare providers, and patient communities, NINDS plays a pivotal role in transforming scientific discoveries into clinical applications, ultimately enhancing the quality of life for individuals affected by neurological conditions.

Locations

Bethesda, Maryland, United States

Bethesda, Maryland, United States

Bamako, , Mali

Patients applied

JF

1 patients applied

Trial Officials

Christopher Grunseich, M.D.

Principal Investigator

National Institute of Neurological Disorders and Stroke (NINDS)

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials